[1] Riu G., Gaba L., Victoria I., Molas G., Do Pazo F., Gómez B., Creus N. & Vidal L (2018) Implementation of a pharmaceutical care programme for patients receiving new molecular-targeted agents in a clinical trial unit. Eur. J. Cancer Care (Engl)., vol. 27, no. 1. doi: 10.1111/ecc.12447.
[2] A. G. Silva, C. Azevedo, L. R. F. Da Mata, and C. I. Vasques, (2017) Adesão De Pacientes Ao Tratamento Com Antineoplásicos Orais: Fatores Influentes. Rev. Baiana Enfermagem, vol. 31, no. 1, pp. 1–12. doi: 10.18471/rbe.v31i1.16428.
[3] S. M. Rosenberg, K. J. Petrie, A. L. Stanton, L. Ngo, E. Finnerty, and A. H. Partridge (2020) Interventions to Enhance Adherence to Oral Antineoplastic Agents: A Scoping Review. J. Natl. Cancer Inst., vol. 112, no. 5, pp. 443–465. doi: 10.1093/jnci/djz244.
[4] B. Battis, L. Clifford, M. Huq, E. Pejoro, and S. Mambourg (2017) The impacts of a pharmacist-managed outpatient clinic and chemotherapy-directed electronic order sets for monitoring oral chemotherapy. J. Oncol. Pharm. Pract., vol. 23, no. 8, pp. 582–590. doi: 10.1177/1078155216672314.
[5] V. Escudero-Vilaplana, A. Ribed, R. M. Romero-Jimenez, A. Herranz-Alonso, and M. Sanjurjo-Saez. (2017) Pharmacotherapy follow-up of key points in the safety of oral antineoplastic agents. Eur. J. Cancer Care (Engl)., vol. 26, no. 3. doi: 10.1111/ecc.12463.
[6] R. Elkaddoum, F. G. Haddad, R. Eid, and H. R. Kourie (2020) Telemedicine for cancer patients during COVID-19 pandemic: Between threats and opportunities. Futur. Oncol., vol. 16, no. 18, pp. 1225–1227. doi: 10.2217/fon-2020-0324.
[7] M. Kimura et al. (2015) Adherence and awareness of the therapeutic intent of oral anticancer agents in an outpatient setting. Oncol. Lett., vol. 9, no. 5, pp. 2341–2346. doi: 10.3892/ol.2015.3027.
[8] J. Thoma, R. Zelkó, and B. Hankó (2016) The need for community pharmacists in oncology outpatient care: a systematic review. Int. J. Clin. Pharm., vol. 38, no. 4, pp. 855–862. doi: 10.1007/s11096-016-0297-2.
[9] J. A. Engle et al. (2018) Assessment of adherence and relative dose intensity with oral chemotherapy in oncology clinical trials at an academic medical center. J. Oncol. Pharm. Pract., vol. 24, no. 5, pp. 348–353. doi: 10.1177/1078155217704989.
[10] L. Timmers, C. C. L. M. Boons, M. Verbrugghe, B. J. F. van den Bemt, A. Van Hecke, and J. G. Hugtenburg (2017) Supporting adherence to oral anticancer agents: Clinical practice and clues to improve care provided by physicians, nurse practitioners, nurses and pharmacists. BMC Cancer, vol. 17, no. 1, pp. 1–12. doi: 10.1186/s12885-017-3110-2.
[11] J. M. Jacobs et al (2017) Treatment satisfaction and adherence to oral chemotherapy in patients with cancer. J. Oncol. Pract., vol. 13, no. 5, pp. e474–e483. doi: 10.1200/JOP.2016.019729.
[12] T. Walle et al (2020) Completion rate and impact on physician-patient relationship of video consultations in medical oncology: A randomised controlled open-label trial. ESMO Open, vol. 5, no. 6, pp. 1–9. doi: 10.1136/esmoopen-2020-000912.
[13] E. S. Koster, D. Philbert, and M. L. Bouvy (2021) Impact of the COVID-19 epidemic on provision of pharmaceutical care in community pharmacies. Res. Soc. Adm. Pharm., vol. 17, no. January, pp. 2002–2004. https://doi.org/10.1016/j.sapharm.2020.07.001.
[14] S. qian Zheng, L. Yang, P. xiang Zhou, H. bo Li, F. Liu, and R. sheng Zhao (2021) Recommendations and guidance for providing pharmaceutical care services during COVID-19 pandemic: A China perspective. Res. Soc. Adm. Pharm., vol. 17, no. 1, pp. 1819–1824. doi: 10.1016/j.sapharm.2020.03.012.
[15] Z. Mahmoudjafari et al. (2020) American Society for Transplantation and Cellular Therapy Pharmacy Special Interest Group Position Statement on Pharmacy Practice Management and Clinical Management for COVID-19 in Hematopoietic Cell Transplantation and Cellular Therapy Patients in the Un. Biol Blood Marrow Transpl., vol. 26, no. January, pp. 1043–1049. doi: https://doi.org/10.1016/j.bbmt.2020.04.005 1083-8791.
[16] L. M. Hess, M. A. Raebel, D. A. Conner, and D. C. Malone (2006) Measurement of Adherence in Pharmacy Administrative Databases: A Proposal for Standard Definitions and Preferred Measures. Ann. Pharmacother., vol. 40, no. 7–8, pp. 1280–1288, Jul. doi: 10.1345/aph.1H018.
[17] E. da C. Lima-Dellamora, C. G. S. Osorio-de-Castro, L. G. D. S. L. Madruga, and T. B. Azeredo (2017) Utilização de registros de dispensação de medicamentos na mensuração da adesão: Revisão crítica da literature. Cad. Saude Publica, vol. 33, no. 3, pp. 1–16. doi: 10.1590/0102-311x00136216.
[18] E. Ream et al. (2020) Telephone interventions for symptom management in adults with cancer. Cochrane Database Syst. Rev., vol. 2020, no. 6. doi: 10.1002/14651858.CD007568.pub2.
[19] F. Yildiz and B. Oksuzoglu (2020) Teleoncology or telemedicine for oncology patients during the COVID-19 pandemic: The new normal for breast cancer survivors?. Futur. Oncol., vol. 16, no. 28, pp. 2191–2195. doi: 10.2217/fon-2020-0714.
[20] S. Suzuki et al. (2020) Impact of outpatient pharmacy interventions on management of thyroid patients receiving lenvatinib. SAGE Open Med., vol. 8, pp. 1–8. doi: 10.1177/2050312120930906.
[21] S. Yokoyama et al.(2018) Oncology pharmacist contributions to treatment with oral anticancer agents in a Japanese community pharmacy setting. Can. Pharm. J., vol. 151, no. 6, pp. 377–382. doi: 10.1177/1715163518802865.
[22] F. Martos-Pérez et al. (2021) The value of telephone consultations during COVID-19 pandemic. An observational study. QJM An Int. J. Med., no. February, pp. 1–6. doi: 10.1093/qjmed/hcab024.
[23] P. A. C. Marques and A. M. G. Pierin (2008) Fatores que influenciam a adesão de pacientes com câncer à terapia antineoplásica oral. ACTA Paul. Enferm., vol. 21, no. 2, pp. 323–329. doi: 10.1590/S0103-21002008000200015.
[24] M. Kimura et al. (2014) Oral anticancer agent medication adherence by outpatients. Oncol. Lett., vol. 8, no. 5, pp. 2318–2324. doi: 10.3892/ol.2014.2480.
[25] E. Mackler, E. M. Segal, B. Muluneh, K. Jeffers, and J. Carmichael (2019) 2018 Hematology/oncology pharmacist association best practices for the management of oral oncolytic therapy: Pharmacy practice standard. J. Oncol. Pract., vol. 15, no. 7, pp. E346–E355. doi: 10.1200/jop.18.00581.
[26] WHO, Medication Without Harm. 2017, p. 16.
[27] W. C. Chou et al. (2019) A nationwide survey of adherence to analgesic drugs among cancer patients in Taiwan: prevalence, determinants, and impact on quality of life. Support. Care Cancer, vol. 27, no. 8, pp. 2857–2867. doi: 10.1007/s00520-018-4599-x.
[28] Cristina do Rosário L. R. Baeta (2016) Estudo da implementação de um modelo de consulta farmacêutica no doente oncológico em regime ambulatório. Dissertação do upgrade ao Mestrado Integrado em Ciências Farmacêuticas. Universidade de Coimbra.
[29] Oliveira, Joana Angélica Avena De; Cordeiro, Benedito Carlos (2012) Atenção farmacêutica às pacientes oncológicas de um hospital de grande porte – Cópia. pp. 6–9, 2012.
[30] L. A. Randolph, C. K. Walker, A. T. Nguyen, and S. R. Zachariah (2018) Impact of pharmacist interventions on cost avoidance in an ambulatory cancer center. J. Oncol. Pharm. Pract., vol. 24, no. 1, pp. 3–8. doi: 10.1177/1078155216671189.